Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared on LinkedIn:
“Kicking off 2026: A New Perspective on Avatrombopag in Aplastic Anemia
I am pleased to start the new year by sharing our latest review article, published in Therapeutic Advances in Hematology.
While Thrombopoietin Receptor Agonists (TPO-RAs) like Eltrombopag have revolutionized the treatment of Aplastic Anemia (AA), hepatotoxicity and dietary restrictions remain significant challenges for many patients.
Our team conducted a comprehensive review of clinical evidence from 2023 to 2025 to evaluate the efficacy and safety of Avatrombopag (AVA) as an alternative.
Key Findings for Clinical Practice:
- High Efficacy: Across the reviewed studies, we observed Overall Response Rates (ORR) ranging from 55% to 85%, with complete response rates reaching up to one-third of treated patients.
- Superior Liver Safety: Unlike earlier agents in this class, Avatrombopag demonstrated a favorable safety profile with no clinically relevant hepatotoxicity reported. It appears safe even for patients with underlying liver dysfunction.
- Rapid Response: Hematologic improvement typically occurred within 1–2 months, aligning well with clinical decision-making timelines.
- Patient Convenience: AVA requires no dietary restrictions and does not undergo significant hepatic metabolism, simplifying management for complex patients.
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
I extend my sincere gratitude to Dr. Mostafa Faisal Mohammed Saleh, Dr. Ahmed Kotb Abdrabou, Dr. Alfadil Haroon, Dr. Hadeel Samarkandi, Dr. Hazza Alzahrani, Dr. Mahmoud Aljurf, Dr. Ali Alahmari.
Read the full review here.”
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25